A detailed history of Cubist Systematic Strategies, LLC transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 99,342 shares of VNDA stock, worth $464,920. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,342
Holding current value
$464,920
% of portfolio
0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.61 - $6.34 $457,966 - $629,828
99,342 New
99,342 $465,000
Q1 2024

May 15, 2024

SELL
$3.47 - $4.61 $431,279 - $572,967
-124,288 Reduced 87.03%
18,529 $76,000
Q4 2023

Feb 14, 2024

SELL
$3.38 - $4.58 $258,546 - $350,337
-76,493 Reduced 34.88%
142,817 $602,000
Q3 2023

Nov 14, 2023

BUY
$4.28 - $6.57 $401,438 - $616,226
93,794 Added 74.73%
219,310 $947,000
Q2 2023

Aug 14, 2023

BUY
$5.9 - $6.95 $581,486 - $684,971
98,557 Added 365.58%
125,516 $827,000
Q1 2023

May 15, 2023

SELL
$6.18 - $7.99 $1.9 Million - $2.45 Million
-306,676 Reduced 91.92%
26,959 $183,000
Q4 2022

Feb 14, 2023

BUY
$6.87 - $10.96 $1.1 Million - $1.76 Million
160,162 Added 92.33%
333,635 $2.47 Million
Q3 2022

Nov 14, 2022

BUY
$9.44 - $11.76 $911,139 - $1.14 Million
96,519 Added 125.42%
173,473 $1.71 Million
Q2 2022

Aug 15, 2022

SELL
$9.31 - $11.84 $55,496 - $70,578
-5,961 Reduced 7.19%
76,954 $839,000
Q1 2022

May 16, 2022

SELL
$10.84 - $16.55 $162,296 - $247,786
-14,972 Reduced 15.3%
82,915 $938,000
Q4 2021

Feb 14, 2022

BUY
$15.69 - $21.14 $928,314 - $1.25 Million
59,166 Added 152.8%
97,887 $1.54 Million
Q3 2021

Nov 15, 2021

SELL
$15.35 - $21.27 $107,158 - $148,485
-6,981 Reduced 15.28%
38,721 $664,000
Q2 2021

Aug 16, 2021

SELL
$15.71 - $21.51 $1.08 Million - $1.48 Million
-68,742 Reduced 60.07%
45,702 $983,000
Q1 2021

May 17, 2021

BUY
$13.42 - $20.28 $1.06 Million - $1.6 Million
79,078 Added 223.6%
114,444 $1.72 Million
Q4 2020

Feb 16, 2021

SELL
$9.77 - $13.81 $473,962 - $669,950
-48,512 Reduced 57.84%
35,366 $465,000
Q3 2020

Nov 16, 2020

SELL
$9.32 - $12.02 $183,743 - $236,974
-19,715 Reduced 19.03%
83,878 $810,000
Q2 2020

Aug 14, 2020

BUY
$9.66 - $12.02 $793,201 - $986,986
82,112 Added 382.25%
103,593 $1.19 Million
Q1 2020

May 15, 2020

SELL
$7.5 - $16.8 $488,032 - $1.09 Million
-65,071 Reduced 75.18%
21,481 $223,000
Q4 2019

Feb 14, 2020

SELL
$12.38 - $17.47 $210,794 - $297,461
-17,027 Reduced 16.44%
86,552 $1.42 Million
Q3 2019

Nov 14, 2019

BUY
$12.27 - $15.79 $255,400 - $328,668
20,815 Added 25.15%
103,579 $1.38 Million
Q2 2019

Aug 14, 2019

BUY
$13.37 - $18.85 $234,844 - $331,100
17,565 Added 26.94%
82,764 $1.17 Million
Q1 2019

May 15, 2019

BUY
$17.59 - $31.05 $716,722 - $1.27 Million
40,746 Added 166.63%
65,199 $1.2 Million
Q4 2018

Feb 14, 2019

SELL
$18.97 - $31.47 $849,059 - $1.41 Million
-44,758 Reduced 64.67%
24,453 $639,000
Q3 2018

Nov 14, 2018

BUY
$18.25 - $23.0 $1.26 Million - $1.59 Million
69,211 New
69,211 $1.59 Million
Q1 2018

May 15, 2018

SELL
$14.05 - $20.2 $33,115 - $47,611
-2,357 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$12.85 - $18.1 $295,935 - $416,843
-23,030 Reduced 90.72%
2,357 $36,000
Q3 2017

Nov 14, 2017

BUY
$15.4 - $18.85 $390,959 - $478,544
25,387
25,387 $454,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $265M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.